New Asthma Diagnosis Codes or Short‐Acting β 2 Agonist Prescriptions After Histoplasmosis Among Patients With Commercial Health Insurance, United States, 2018–2023
Mycoses · 2025
DOI: 10.1111/myc.70109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mycoses, 2025. Verfasst von Ian Hennessee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Histoplasmosis, Asthma, Adrenergic beta-2 Receptor Agonists. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural CDC HHS.
Abstract (Originalsprache)
Background
Although several fungal infections have been linked to asthma development, the relationship between histoplasmosis and asthma development has not been fully described.
Objectives
To assess the incidence of new asthma diagnosis codes or short‐acting β 2 agonist (SABA) prescription in the year following histoplasmosis diagnosis and identify potentially related factors.
Methods
We used a large health insurance claims database to identify patients with histoplasmosis with and without an asthma diagnosis code or a short‐acting β 2 agonist prescription in the year after diagnosis.
Results
Among 1819 patients diagnosed with histoplasmosis, 252 (13.9%) received a new asthma diagnosis or SABA prescription in the subsequent year, more than double the proportion in the general population (5.8%). Pulmonary histoplasmosis and symptoms such as dyspnea and wheezing were associated with asthma diagnosis or SABA receipt.
Conclusion
These findings suggest that histoplasmosis may predispose certain patients to airway hyperreactivity, particularly those with acute pulmonary symptoms. Further research is needed to elucidate potential mechanisms underlying these findings, which could inform strategies to mitigate post‐infectious airway disease in affected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
ORCID-Profile: Kaitlin Benedict, Dallas J Smith
Förderung
- Intramural CDC HHS
Zitieren
APA
Hennessee, I., Benedict, K., Smith, D. J., & Barros, N. (2025). New Asthma Diagnosis Codes or Short‐Acting β 2 Agonist Prescriptions After Histoplasmosis Among Patients With Commercial Health Insurance, United States, 2018–2023. Mycoses. https://doi.org/10.1111/myc.70109
Vancouver
Hennessee I, Benedict K, Smith DJ, Barros N. New Asthma Diagnosis Codes or Short‐Acting β 2 Agonist Prescriptions After Histoplasmosis Among Patients With Commercial Health Insurance, United States, 2018–2023. Mycoses. 2025. doi:10.1111/myc.70109
BibTeX
@article{Hennessee2025,
author = {Hennessee, Ian and Benedict, Kaitlin and Smith, Dallas J and Barros, Nicolas},
title = {New Asthma Diagnosis Codes or Short‐Acting β 2 Agonist Prescriptions After Histoplasmosis Among Patients With Commercial Health Insurance, United States, 2018–2023},
journal = {Mycoses},
year = {2025},
doi = {10.1111/myc.70109}
}
EUVIMED